Bank of America Securities analyst Tazeen Ahmad has reiterated their bullish stance on ALNY stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tazeen Ahmad has given his Buy rating due to a combination of factors including Alnylam Pharma’s strong financial performance and strategic advancements. The company reported impressive second-quarter revenues for its products, particularly Amvuttra, which exceeded both internal and consensus expectations. This robust performance led to an increase in the TTR franchise guidance, reflecting confidence in the ATTR-CM launch and meeting high investor expectations.
Additionally, Alnylam’s management has made significant progress in expanding Amvuttra’s market access, with favorable payor policies and broad uptake across patient and prescriber segments. The company’s promising siRNA pipeline, including ongoing trials for nucresiran and positive data for mivelsiran, suggests potential long-term growth opportunities. These factors, combined with a raised price objective, underpin the Buy rating recommendation.
According to TipRanks, Ahmad is an analyst with an average return of -4.2% and a 48.68% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Argenx Se, ACADIA Pharmaceuticals, and Incyte.
In another report released today, Barclays also maintained a Buy rating on the stock with a $460.00 price target.